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Abstract 
Background: Ranolazine is a new anti-anginal drug that acts via late sodium current inhibition, and has been shown 
to improve diastolic dysfunction in isolated myocytes. Diastolic dysfuntion is common in patients with aortic steno-
sis (AS), and precedes symptom development and systolic dysfunction. The purpose of this study was to assess the 
effects of ranolazine on peak early diastolic strain rate (PEDSR) and exercise capacity in patients with AS.
Methods: Patients with asymptomatic moderate to severe AS and diastolic dysfunction underwent trans-thoracic 
echocardiography, exercise testing and cardiac magnetic resonance (CMR) imaging at baseline, 6 weeks after com-
mencing ranolazine and at 10 weeks (4 weeks after discontinuation). Diastolic function was assessed using PEDSR 
measured on tagged CMR images.
Results: Fifteen patients (peak pressure gradient 48.8 ± 12.4 mmHg, mean pressure gradient 27.1 ± 7.5 mmHg, 
aortic valve area 1.26 ± 0.31 cm2) completed the week-6 visit and 13 completed the final visit. Global PEDSR did not 
significantly increase from baseline (0.79 ± 0.15) to week-6 (0.86 ± 0.18, p = 0.198). There was a borderline significant 
increase in total exercise duration from 10.47 ± 3.68 min to 11.60 ± 3.25 min (p = 0.06).
Conclusion: This small pilot study did not show a significant improvement in diastolic function with the use of 
ranolazine in asymptomatic patients with moderate-severe AS. Further studies with a larger population may be 
indicated.
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Background
Aortic stenosis (AS) is the commonest valve lesion 
requiring surgery in the developed world [1], and its 
prevalence is increasing with an ageing population. It is 
common in the elderly [2], with up to 3 % of the popu-
lation over 75  years of age having severe AS [3]. The 
prognosis of symptomatic AS is greatly improved by aor-
tic valve replacement and surgery is universally recom-
mended in this situation [4, 5]. However, many patients 
remain symptomatic following surgery and there are 
currently no medical therapies which are of proven value 
in AS or other conditions characterised by diastolic 
dysfunction.
The mechanism of symptom generation in AS is 
unclear. The presence of left ventricular hypertrophy 
(LVH) and diastolic dysfunction appear to be important 
determinants of exercise capacity in AS [6–8]. Follow-
ing surgery, slow improvements in exercise capacity are 
seen [9], mirroring reductions in LV mass [10–12]. The 
mechanism of exercise intolerance is probably related to 
persistent diastolic dysfunction due to incomplete resolu-
tion of interstitial myocardial fibrosis [11, 12]. Addition-
ally, subendocardial ischemia occurs in AS patients, even 
in those with angiographically normal epicardial coro-
nary arteries [13]. Such ischaemia is likely to exacerbate 
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diastolic dysfunction and in turn perpetuate further 
ischaemia.
Cardiac magnetic resonance imaging (CMR) allows 
accurate quantification of LV mass, volumes and sys-
tolic function. Its also allows measurement of myocardial 
deformation in the form of strain and strain rates, and 
peak early diastolic strain rate (PEDSR), which measures 
the rate of myocardial relaxation, and is a largely load-
independent measure of diastolic function [14]. PEDSR 
has been shown to be a sensitive marker of diastolic dys-
function in patients with type-II diabetes [15], and has 
been widely used in other CMR studies [16, 17].
Ranolazine is a newly licensed drug for the treatment 
of chronic stable angina [18, 19]. Ranolazine, through the 
inhibition of the late sodium (Na+) current, decreases 
intracellular calcium concentration and shortens the 
action potential duration, without clinically significant 
effects on heart rate or blood pressure. In experimental 
models, ranolazine has been shown to improve diastolic 
dysfunction in isolated myocytes [20–22] and reduce 
progressive remodelling in a dog model of heart failure 
[23]. In small pilot studies of patients with angina, ranola-
zine decreased reversible ischaemia on scintigraphy [24] 
and improved echocardiographic parameters of diastolic 
and systolic function [25].
Objectives
The objectives of this pilot study were to assess the effects 
of Ranolazine on diastolic dysfunction, myocardial per-
fusion reserve (MPR) and exercise capacity in asympto-
matic patients with moderate to severe AS with evidence 
of diastolic dysfunction and/or LVH.
Methods
Study design
The study was a prospective, single centre, open label, 
single group, proof-of-concept study, with blinded end-
point analysis (EduraCT number 2011-000111-26). The 
United Kingdom National Research Ethics Service (Har-
row, Reference 11/LO/0553) approved the study and 
written informed consent was obtained from all subjects 
before participation. All imaging was analysed blinded to 
patient or visit information and the anonymised data was 
sent to the clinical trials unit (CTU), for unblinding and 
analysis at the end of the study.
Study population
Patients were prospectively recruited from a single Car-
diac centre. Inclusion criteria were: (1) moderate or 
severe AS (two or more of aortic valve area <1.5cm2, 
peak pressure gradient >36 mmHg, mean pressure gradi-
ent >20 mmHg), (2) asymptomatic, (3) evidence of dias-
tolic dysfunction (MV inflow: E/A <1 or TDI: septal E/e’ 
>15, lateral E/e’ >10 on echocardiogram) or LVH (maxi-
mum wall thickness  >13  mm on echocardiography), (4) 
age >18 years. Exclusion criteria were: (1) history of coro-
nary artery bypass graft, myocardial infarction or angio-
graphic coronary artery disease (>50 % luminal stenosis 
if previously undertaken), (2) atrial fibrillation, (3) severe 
asthma (4) severe renal impairment (eGFR <30 ml/min), 
(5) hepatic impairment, (6) Concurrent administration 
of strong CYPA4 inhibitors or class I/III anti-arrhythmic 
agents, (7) QTc prolongation >470  ms, (8) Females of 
childbearing potential, (9) Use of >20 mg of simvastatin 
or >1000 mg of metformin during the study period.
Study conduct
Consented patients underwent venepuncture, electrocar-
diography (ECG), trans-thoracic echocardiography, exer-
cise testing and stress CMR, before being commenced 
on 500  mg bd of ranolazine (C24H33N3O4, Gilead Sci-
ences). This was up-titrated to 750 mg bd after 2 weeks, 
if tolerated, and continued for another 4 weeks. The study 
involved four outpatient visits to the hospital as outlined 
in Fig. 1. All investigations were repeated at week-6 and 
again at week-10 (4 weeks after stopping ranolazine).
Echocardiography
Echocardiography was performed according to the 
American Society of Echocardiography recommenda-
tions [26], and blinded, off-line analysis was performed 
using Xcelera v3.3.1 (Philips, Netherlands) workstation. 
In addition to the standard 2D, colour flow and Doppler 
images to assess AS severity and LV function, diastolic 
function was assessed using pulsed-wave Doppler and 
tissue Doppler, to get the E-wave, A-wave, E/A and sep-
tal and lateral E/e’. Continuous-wave Doppler data was 
acquired at rest as well as post-exercise. The left ventricu-
lar rate pressure product (LVRPP), a surrogate marker of 
myocardial oxygen consumption, was calculated at rest 
and at peak exercise using the following formula:
 
(LVRPP left ventricular rate pressure product in 
mmHg.bpm, PPG peak aortic valve pressure gradient in 
mmHg, SBP peak systolic blood pressure in mmHg; HR 
heart rate in beats per minute).
Exercise testing
A treadmill test was performed, with continuous ECG 
monitoring, using the modified Bruce Protocol. The sub-
jects were exercised till they had achieved at least 85 % of 
their maximal predicted heart rate, a limiting symptom 
(chest pain, significant dyspnoea or dizziness) or another 
pre-specified reason for stopping (ST depression >5 mm, 
LVRPP = (PPG + SBP) × HR
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significant arrhythmia, systolic blood pressure (SBP) 
>250 mmHg or diastolic blood pressure >120 mmHg or a 
fall in SBP >20 mmHg).
CMR acquisition
CMR was performed on a 3-tesla (T) scanner (Mag-
netom Skyra, Siemens AG, Healthcare Sector, Erlangen, 
Germany) using an 18-channel phased array receiver 
coil (Fig.  2). Steady state free precession end-expiratory 
breath-held cine images were acquired, with retrospec-
tive ECG triggering, to determine LV volumes, mass and 
function. Tagged images were acquired at three short-
axis slices (basal, mid, apical), using spatial modulation 
of magnetization (SPAMM): slice thickness 8  mm, grid 
tag spacing 8 mm, TR 3.6 ms, TE 2.4 ms, flip angle 10°, 
temporal resolution 46 ms and prospective gating as pre-
viously described [27]. Stress imaging was performed at 
the same three short-axis slice positions after inducing 
pharmacological vasodilation with an infusion of adeno-
sine at 140 mg/kg/min for 3 min or until a haemodynamic 
response and/or symptoms were achieved. First pass per-
fusion imaging was performed with 0.025  mmol/kg of 
contrast (Gadovist, Bayer Pharma AG, Germany) at stress 
and again after 10  min of rest, using a saturation recov-
ery gradient-echo sequence, during breath holding. This 
was followed by a top-up of 0.1 mmol/kg to bring the total 
dose of contrast to 0.15 mmol/kg, before late gadolinium 
imaging (LGE) was performed after a delay of 10 min.
CMR analysis
CMR42 v4.2 (Circle Cardiovascular Imaging, Calgary, 
Alberta, Canada) was used to calculate the LV mass and 
volume data. Circumferential peak systolic strain (PSS), 
peak systolic strain rate (PSSR) and peak early diastolic 
strain rate (PEDSR) were calculated for each slice and 
globally (average of base, mid, apex) using the InTag 
post-processing plugin (Creatis, Lyon, France) for OsiriX 
(Geneva, Switzerland) on the tagged images as previously 
described [27]. The segmental strain outputs generated 
by the software were post-processed using in-house 
Microsoft excel spreadsheets (Microsoft Office 2011, 
California, USA), in order to obtain average strain and 
strain rate curves for each slice. Perfusion analysis was 
performed using QMass v7.1 (Medis Medical Imaging 
Systems, Netherlands), to produce graphs of signal inten-
sity against time. Absolute myocardial blood flow (MBF) 
quantification was performed as previously described 
[28, 29], using model-independent deconvolution. Myo-
cardial perfusion reserve (MPR) was calculated by divid-
ing hyperaemic MBF by resting MBF.
Fig. 1 Study overview and recruitment (ECG electrocardiogram, TTE trans-thoracic echocardiogram, CMR cardiac magnetic resonance imaging, ET 
exercise test, SE side effects, CAD coronary artery disease)
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Endpoints
The primary hypothesis was that late sodium current 
inhibition with ranolazine would improve PEDSR, a 
measure of diastolic dysfunction, on tagged MRI. Sec-
ondary endpoints included MPR, exercise capacity and 
echocardiographic markers of diastolic function (E/E’).
Statistical analysis and power calculation
In a previous group of eight AS patients tested 
2 weeks apart, diastolic strain rate was 0.73 ± 0.22 and 
0.71  ±  0.21 with paired mean difference of 0.04 and 
SD of 0.16. Sixteen patients with analysable images 
would allow us to detect a difference of 0.12 in diastolic 
strain rate with 80  % power, p  <  0.05 and two-tailed. 
To allow for drop-outs and unanalysable image quality, 
we planned to recruit 20 patients. Statistical tests were 
performed using SPSS 20.0 software (Statistical Pack-
age for the Social Sciences, Chicago, IL). Normality 
was assessed using the Shapiro–Wilk test, histograms 
and Q–Q plots. Continuous data are expressed as mean 
(standard deviation). Paired-samples t tests were used 
to compare parameters between different visits. In addi-
tion, repeated measure analysis of variance (ANOVA) 
was used to compare parameters across the three vis-
its. The results were further analysed after splitting 
the patients according to the median MPR, into low 
and high-MPR subgroups, and patient characteristics 
between the two sub-groups were compared using inde-
pendent t test. Two-factor repeated measure ANOVA 
analysis was used to compare change in global PEDSR 
between the two sub-groups.
Results
Twenty patients consented to take part in the study but 
one patient was excluded after ECG showed atrial fibril-
lation. Nineteen completed the baseline visit, 4 withdrew 
before visit-3 and therefore, a total of 15 patients had data 
for the primary endpoint analysis at 6 weeks (Fig. 1). The 
demographic data for these patients (as well as the sub-
groups) is shown in Table 1. Two continued on the lower 
dose of ranolazine (500 mg BD) due side effects with the 
higher dose. Another two patients were unable to attend 
the week-10 visit, making the full analysis sample (FAS) 
consist of 13 patients.
Primary endpoint: PEDSR
In these data, there is insufficient evidence that global 
PEDSR changed significantly from the baseline value to 
week-6, although the mean PEDSR increased numeri-
cally (Table  2). A similar pattern was demonstrated for 
each slice individually (change in PEDSR from baseline 
to week-6 from 0.818 to 0.893 for basal, 0.829 to 0.841 
for mid and 0.756 to 0.790 for apical slices). For the FAS 
sample, global PEDSR was: baseline (0.82 ± 0.13), week-6 
Fig. 2 Cardiac MRI protocol used (4/2/3 C 4/2/3 chamber, LV left ventricular, LA left atrial, LVOT left ventricular outflow track, LGE late gadolinium 
enhancement)
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(0.87 ± 0.19), and week-10 (0.81 ± 0.21) (p > 0.05 using 
both paired t tests and repeated measures ANOVA anal-
ysis) (Additional file 1: Table S1).
Secondary endpoints
The results of the secondary endpoints are shown in 
Table 2. There was no significant change in global MPR or 
echocardiographic measures of diastolic dysfunction. The 
total exercise duration increased from 10.47 ± 3.68 min 
to 11.60  ±  3.25  min at week-6 (n  =  15), which was of 
borderline significance (p = 0.06), but remained elevated 
at week-10 (Additional file  2: Table S2). Figure  3 shows 
the total exercise duration for all patients at each visit 
(baseline: n = 19, week-6: n = 15, week-10: n = 13). The 
maximal HR and SBP tended to be lower at week-6, lead-
ing to a non-significant reduction in exercise LVRPP at 
week-6. There was no change in the resting values of HR, 
SBP or LVRPP.
Subgroup analysis by MPR
The patients were divided into low and high-MPR sub-
groups based on the median MPR of 2.79. The groups 
were well matched for age, gender, AS severity and rest-
ing haemodynamic data (Table 1). There was a non-sig-
nificant increase in global PEDSR from baseline to week-6 
in the low-MPR sub-group (0.82 ±  0.17 to 1.03 ±  0.27, 
p  =  0.139), which was not present in the high-MPR 
subgroup (Fig. 4), though this difference remained non-
significant (p  >  0.05) on two-factor repeated measures 
ANOVA analysis. Table 3 shows the results of the PEDSR 
and exercise data for the FAS sample, according to the 
sub-groups, which were not statistically significant.
Discussion
PEDSR
This single-centre pilot study aimed to assess the effects 
of ranolazine on diastolic function in patients with mod-
erate to severe AS and evidence of diastolic dysfunc-
tion. There was no evidence in these data that ranolazine 
improved PEDSR.
The effect of ranolazine in improving diastolic function 
has previously been demonstrated in both animal models 
[21, 30] and experimental in vitro studies in human myo-
cytes [20, 22]. The exact mechanism for this effect is not 
entirely clear, but is thought to be related to the late Na+ 
current inhibition by ranolazine, leading to a decrease in 
intra-cellular-Na+ dependent intracellular calcium con-
centration [20]. There have only been a few small clini-
cal studies assessing the effect of ranolazine on diastolic 
function. In a study of ischaemic heart disease patients 
with previous MI (n = 15), Ranolazine infusion improved 
regional diastolic function, measured by 2-dimensional 
Table 1 Demographic data for overall study population and high and low-MPR subgroups
BMI body mass index, LVRPP left ventricular rate pressure product, LVMI left ventricular mass indexed to body surface area, LVEDVI left ventricular end diastolic volume 
indexed to body surface area, LVEF left ventricular ejection fraction
Independent t test used to compare low and high-MPR subgroups
Parameter Overall (n = 15) Low-MPR (n = 7) High-MPR (n = 8)
Age (years) 65.9 ± 9.67 63.6 ± 10.3 67.9 ± 9.3
Gender ratio (male/female, n (%)) 12/3 (80.0/20.0) 6/1 (85.7/14.3) 6/2 (75.0/25.0)
BMI (kg/m2) 29.3 ± 3.36 29.3 ± 4.3 29.3 ± 2.6
Heart rate (bpm) 74.5 ± 11.8 78.6 ± 9.4 71.0 ± 13.2
Systolic blood pressure (mmHg) 153.0 ± 23.6 153.0 ± 29.3 153.0 ± 19.6
Diastolic blood pressure (mmHg) 81.7 ± 11.1 83.7 ± 11.3 80.0 ± 11.4
Echocardiographic Data
 Peak pressure gradient (mmHg) 48.8 ± 12.4 50.5 ± 13.0 49.2 ± 12.7
 Mean pressure gradient (mmHg) 27.1 ± 7.5 27.4 ± 7.5 27.0 ± 8.1
 Aortic valve area (cm2) 1.26 ± 0.31 1.31 ± 0.40 1.20 ± 0.21
 E/A 0.77 ± 0.16 0.79 ± 0.17 0.76 ±0.17
 Average septal E/e’ 12.94 ± 3.91 11.19 ± 1.01 14.48 ± 4.89
 Average lateral E/e’ 10.65 ± 3.49 9.34 ± 2.90 11.80 ± 3.73
 Resting LVRPP (mmHg.bpm) 14,424.3 ± 3054.0 15,400.5 ± 2627.3 13,570.2 ± 3309.1
 Exercise LVRPP (mmHg.bpm) 36,041.3 ± 5235.1 38,888.7 ± 4365.0 34,449.0 ± 5656.8
 CMR data
 LVMI (g/m2) 66.72 ± 15.35 68.2 ± 13.9 65.4 ± 17.3
 LVEDVI (ml/m2) 85.02 ± 15.92 81.59 ± 17.33 88.03 ± 15.07
 LVEF (%) 58.29 ± 3.81 58.3 ± 3.3 58.3 ± 4.4
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Table 2 Primary and secondary endpoint measures: baseline vs week-6 (n = 15)
Abbreviations as Table 1. PEDSR peak early diastolic strain rate, PSS peak systolic strain, PSSR peak systolic strain rate, MBF myocardial blood flow, MPR myocardial 
perfusion reserve, LVESV left ventricular end systolic volume, HR heart rate, SBP systolic blood pressure. All p > 0.05
Parameter Baseline Week-6 p (paired t test)
MRI parameters
 PEDSR (1/s) 0.79 ± 0.151 0.86 ± 0.181 0.198
 PSS (%) −17.44 ± 2.57 −17.53 ± 3.98 0.907
 PSSR (1/s) −0.99 ± 0.203 −1.04 ± 0.208 0.436
 MPR 2.68 ± 0.634 2.52 ± 0.614 0.452
 LVEDV (ml) 173.7 ± 47.64 170.1 ± 59.02 0.624
 LVESV (ml) 73.3 ± 25.26 74.3 ± 29.38 0.509
 EF (%) 58.3 ± 3.81 56.7 ± 4.81 0.080
Exercise parameters
 Resting HR (bpm) 74.5 ± 11.8 74.4 ± 13.7 0.963
 Resting SBP (mmHg) 153.0 ± 23.6 147.2 ± 17.3 0.208
 Exercise duration (min) 10.47 ± 3.68 11.60 ± 3.25 0.062
 Max HR (bpm) 143.5 ± 10.7 139.6 ± 15.5 0.273
 Max SBP (mmHg) 182.9 ± 20.5 174.5 ± 25.8 0.133
 Resting LVRPP (mmHg.bpm) 14,424.3 ± 3054.0 14,514.1 ± 3591.6 0.903
 Exercise LVRPP (mmHg.bpm) 36,041.3 ± 5235.1 34,516.9 ± 6538.4 0.313
Biomarker
 NT-proBNP (pmol/L) 48.54 ± 82.43 51.64 ± 73.28 0.715
Echocardiographic parameters
 E/A 0.773 ± 0.163 0.783 ± 0.169 0.765
 Septal E/e’ 12.94 ± 3.91 13.79 ± 2.86 0.258
 Lateral E/e’ 10.65 ± 3.49 10.62 ± 3.43 0.979
Fig. 3 Total exercise duration for all patients exercised at each visit (p = 0.07 for baseline vs week-6, p = 0.73 for week-6 vs week-10)
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invasive LV angiograohy in non-infarcted ischaemic seg-
ments [31]. Another small study of patients with stable 
angina (n  =  22) demonstrated improvement in some 
echocardiographic parameters of diastolic function, but 
not others [25]. A case report documented improvement 
in ischaemic burden and symptoms in a patient with 
patent grafts but on-going ischaemia, most likely due 
to microvascular and diastolic dysfunction [32]. Finally, 
a recently published randomised trial of ranolazine in 
patients with heart failure with preserved EF (n  =  20) 
failed to demonstrate improvement in echocardiographic 
measures of diastolic function [33]. A limitation in all the 
above-mentioned studies may be their small sample sizes.
The lack of statistical significance in our study may 
not reflect a lack of efficacy. The sample size of the study 
was small, with only fifteen patients having analysable 
tagging images for the primary endpoint, compared to an 
anticipated 16 at inception. Since the study commenced, 
we have also shown that PEDSR may be less reproduc-
ible using tagging (SPAMM) at 3T, as used in this study, 
compared to CSPAMM tagging at 1.5T that was used to 
estimate the sample size [27]. Additionally, on discontinu-
ation, mean PEDSR tended to return towards the baseline 
value, suggesting a possible genuine effect of ranolazine. 
Sub-group analysis also demonstrated interesting differ-
ences, with mean PEDSR showing some improvement in 
the low-MPR subgroup- albeit this effect was only strik-
ing in two patients, and may represent chance (Fig. 4). The 
suggestion that ranolazine may have greater efficacy in 
improving diastolic function in those with more advanced 
disease (reduced perfusion reserve [28]) and ischaemia 
is purely a hypothesis at this stage. Finally, the maximum 
Fig. 4 Change in peak early diastolic strain rate (PEDSR-top panels) and myocardial perfusion reserve (MPR-bottom panels) in low-MPR (left) and 
high-MPR (right) subgroup
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dose of ranolazine used in our study was 750 mg bd (with 
two patients continuing on 500  mg bd), which is lower 
than the dose of 1000  mg bd used in most other studies 
mentioned above, which may partially account for the lack 
of efficacy.
MPR
Our study did not demonstrate improvement in global 
MPR in the overall population following 6  weeks of 
ranolazine therapy. In a previous open-label pilot study 
of patients with coronary artery disease and perfusion 
defects on exercise SPECT myocardial perfusion imag-
ing (n  =  20), 4  weeks of treatment with ranolazine led 
to an improvement in myocardial perfusion pattern and 
severity [24]. This is thought to occur due to reduced 
diastolic wall stiffness caused by the late Na+ current 
inhibition by ranolazine, leading to reduced extra-vas-
cular compression of the coronary microcirculation, 
and improved myocardial blood flow. However, another 
study by the same group using vasodilator stress (n = 18), 
failed to show an improvement in myocardial perfusion 
[34]. Exercise testing induces true ischaemia by a supply/
demand mismatch, whereas vasodilator-stress induced 
perfusion defects result from regional heterogeneity in 
blood flow, which may not activate the late Na+ current. 
In a more recent pilot study of patients with microvas-
cular angina, ranolazine did not lead to an improvement 
in coronary flow reserve, measured by Doppler echocar-
diography, in response to adenosine or cold pressor test 
[35].
Exercise capacity
The total exercise time did show an increase at week-6, 
which was close to reaching statistical significance. This 
observation lends weight to the hypothesis that the small 
increase in PEDSR seen may be significant. We can-
not discount that the increase in exercise capacity was 
related to improved technique on the treadmill, as there 
was no reduction in duration at week-10. However, the 
increase in exercise duration at week-6 was associated 
with a slightly reduced peak heart and blood pressure 
compared to baseline, and therefore a slightly lower 
exercise LVRPP (a measure of myocardial work), that 
were not sustained at week 10.
Ranolazine may increase myocardial efficiency during 
exercise, and the mechanism for this may be related to an 
improvement in PEDSR. Ranolazine has previously been 
shown to increase exercise duration in multiple studies 
of patients with chronic stable angina [18, 19, 36]. In the 
study of patients with HFpEF, ranolazine improved the 
VE/VCO2 slope, an index of ventilatory response to exer-
cise, as well as the exercise duration [33].
Limitations
The major limitation of this study is its small sample 
size, with the results not reaching statistical significance. 
However the study was always planned as a pilot and 
the primary purpose was to assess the effect size. This 
hypothesis-generating study has certainly shown some 
interesting signals that merit further investigation in 
larger trials.
Conclusions
In this pilot study, ranolazine did not show a significant 
improvement in diastolic dysfunction or MPR, in patients 
with moderate to severe AS. Given the low power of the 
current study, a larger study in patients with diastolic 
dysfunction is warranted and preferably conducted at 
1.5T.
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Additional file 1: Tabble S1. Tagging measured PEDSR for FAS popula-
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Abbreviations as Table 1. All p > 0.05. Low MPR = MPR < 2.79, n = 7; High MPR = MPR ≥ 2.79, n = 8)
Parameter Baseline Week-6 Week-10
Group A (Low-MPR)
 Global PEDSR 0.88 ± 0.80 1.03 ± 0.30 0.86 ± 0.15
 Exercise time (min) 11.0 ± 3.6 11.2 ± 3.8 11.5 ± 3.6
 Exercise LVRPP (mmHg.bpm) 39,148.9 ± 3052.2 35,417.1 ± 7042.9 36,882.7 ± 5799.2
Group B (High-MPR)
 Global PEDSR 0.80 ± 0.19 0.75 ± 0.12 0.76 ± 0.28
 Exercise time (min) 11.8 ± 3.7 11.7 ± 3.7 11.8 ± 4.2
 Exercise LVRPP (mmHg.bpm) 33,615.0 ± 6402.4 33,085.4 ± 7839.0 34,357.3 ± 4188.5
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